Jacobio Pharma, a clinical-stage oncology company dedicated to developing therapies toward undruggable targets, today presented preliminary Phase I data of BET inhibitor JAB-8263 to treat myelofibrosis (MF) at the 2024 ASH (American Society of Hematology) Annual Meeting in San Diego, California.
The data showed that JAB-8263 was well tolerated with Recommended Phase 2 Dose (RP2D) being 0.3mg QD. The preliminary efficacy data for JAB-8263 monotherapy in MF are promising, as most patients demonstrated spleen volume reduction (SVR) and total symptom score (TSS) reduction.
HealthTech Insights: ESYA Labs Partners with Alamar Biosciences to Advance Biomarker Detection and Diagnostics for Neurological Diseases
As of the data cutoff date of Oct 17, 2024, 16 patients with intermediate-/high-risk MF have been enrolled, and 13 patients have undergone at least one post-treatment efficacy assessment.
- All patients showed a mean SVR-19.95%at week 24 and -26.16% at best response.
- Two patients achieved ≥35% SVR, and an SVR of -34.9% was observed in one patient.
- Six of ten (60%) patients experienced a ≥50% reduction in TSS at week 24.
- The best response of SVR in 2 of 8 patients (JAK inhibitors-treated) was -41.2% and -34.9%, respectively.
- At week 24, 3 of 6 (50%) patients (JAK inhibitors-treated) achieved TSS50.
HealthTech Insights: Hyundai Supports UCI Health with Diabetes Donation
The monotherapy of JAB-8263 expansion in MF and solid tumor is ongoing. Andrea Wang-Gillam M.D., Ph.D., Chief Medical Officer and Global Head of R&D at Jacobio said, “The preliminary data demonstrated the promising clinical value of our potent BET inhibitor in MF. We will continue exploring for broader indications for JAB-8263, hoping to bring hope to more cancer patients.”
To participate in our interviews, please write to our HelthTech Media Room at news@intentamplify.com
Source – Prnewswire
